Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Revolution Medicines (RVMD) has provided an announcement.
The board of a company expanded its size to ten directors and welcomed Frank K. Clyburn, Jr. as a new independent director, set to serve until the 2025 annual stockholders’ meeting. Clyburn brings extensive experience from his CEO role at International Flavors & Fragrances and leadership positions at Merck, Sanofi Aventis, and Marion Laboratories, as well as past board membership at DuPont de Nemours. His appointment comes with an equity incentive package, comprising stock options and restricted stock units, vesting over three years, alongside standard director compensation and indemnification agreements.
For an in-depth examination of RVMD stock, go to TipRanks’ Stock Analysis page.